Evidence map›Paper›PMID 40069490›Full record

ArticleActa pharmacologica Sinica2025

Oral FPR2/ALX modulators tune myeloid cell activity to ameliorate mucosal inflammation in inflammatory bowel disease.

Wen-Sheng Yang, Qing Liu, Yang Li, Guan-Yi Li, Shi Lin, Jie Li, Lin-Yu Li, Yuan Li, Xi-Lin Ge, Xiao-Zhen Wang and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmacologica Sinica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Wen-Sheng Yang *Department of Clinical Pharmacy, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, 201102, China.
Qing Liu *The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Yang LiDepartment of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Guan-Yi LiSchool of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
Shi LinResearch Center for Deepsea Bioresources, Sanya, 572025, China.
Jie LiDepartment of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Lin-Yu LiDepartment of Clinical Pharmacy, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, 201102, China.
Yuan LiResearch Center for Deepsea Bioresources, Sanya, 572025, China.
Xi-Lin GeDepartment of Clinical Pharmacy, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, 201102, China.
Xiao-Zhen WangResearch Center for Deepsea Bioresources, Sanya, 572025, China.
Wei WuDepartment of Clinical Pharmacy, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, 201102, China.
Jun YanDepartment of Laboratory Animal Science, Fudan University, Shanghai, 200032, China.
Guang-Fei WangDepartment of Clinical Pharmacy, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, 201102, China.
Qing-Tong ZhouDepartment of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Qiang LiuDepartment of Neurology, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Ming-Wei WangDepartment of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China. mwwang@simm.ac.cn.
Zhi-Ping LiDepartment of Clinical Pharmacy, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, 201102, China. zpli@fudan.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current treatments of inflammatory bowel disease (IBD) largely depend on anti-inflammatory and immunosuppressive strategies with unacceptable efficacy and adverse events. Resolution or repair agents to treat IBD are not available but potential targets like formyl peptide receptor 2 (FPR2/ALX) may fill the gap. In this study we evaluated the therapeutic effects of two small molecule FPR2/ALX modulators (agonist Quin-C1 and antagonist Quin-C7) against IBD. We first analyzed the cryo-electron microscopy structure of the Quin-C1-FPR2 in complex with heterotrimeric G

Indexed as

Anti-Inflammatory AgentsColitisInflammatory Bowel DiseasesMyeloid CellsReceptors, Formyl PeptideReceptors, LipoxinAdministration, OralAnimalsDextran SulfateDisease Models, AnimalHumansInflammationIntestinal MucosaMaleMiceMice, Inbred C57BLAnti-Inflammatory AgentsDextran Sulfateformyl peptide receptor 2, mouseReceptors, Formyl PeptideReceptors, LipoxinFPR2/ALXIBDmacrophagesneutrophilsQuin-C1Quin-C7

Identifiers

PMID40069490
PMCPMC12205095

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.